Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34+ cells: A comparison with human bone marrow-derived mesenchymal stem cells

Luan, Xiying; Li, Guangyun; Wang, Guoyan; Wang, Feifei; Lin, Yansong

doi:10.1016/j.tice.2012.09.002

Cited by 46 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that INFg and PD-L1 are not the only molecules that are involved in the immunosuppressor effect of MSCs from the three sources. Our results seem to contradict previous reports in which the presence of MSCs from BM, UCB, PL, AT, and Wharton's jelly, either did not affect or decrease IFNg secretion by activated T cells [20,45,58,59]; however, it was recently reported that MSCs-mediated effects on IFNg secretion depend on the T-cell source and the type of activation and the presence of MSCs even favor the secretion of IFNg by CD3 + T cells activated with anti-CD3/ CD28 [14].…”

Section: Discussioncontrasting

confidence: 99%

“…These studies are important because MSCs act on many of the leukocyte subsets involved directly or indirectly in regulating the immune response in vivo [2,3,24,44]. However, few studies have analyzed BM-and PL-MSCs-mediated immunosuppression on CD3 + T-cell-enriched populations [10,14,25,45], which is important in the context of GVHD, because they are the major effector cells in this disease [39]. Additionally, the immunosuppressive effects of UCB-MSCs on this T-cell population remain unknown.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Human Mesenchymal Stromal Cells from Adult and Neonatal Sources: A Comparative In Vitro Analysis of Their Immunosuppressive Properties Against T Cells

Castro-ManrrezaMarta

MayaniHéctor

García

et al. 2014

Stem Cells and Development

View full text Add to dashboard Cite

Bone marrow-mesenchymal stromal cells (BM-MSCs) have immunosuppressive properties and have been used in cell therapies as immune regulators for the treatment of graft-versus-host disease. We have previously characterized several biological properties of MSCs from placenta (PL) and umbilical cord blood (UCB), and compared them to those of BM-the gold standard. In the present study, we have compared MSCs from BM, UCB, and PL in terms of their immunosuppressive properties against lymphoid cell populations enriched for CD3 + T cells. Our results confirm the immunosuppressive potential of BM-MSCs, and demonstrate that MSCs from UCB and, to a lesser extent PL, also have immunosuppressive potential. In contrast to PL-MSCs, BMMSCs and UCB-MSCs significantly inhibited the proliferation of both CD4+ and CD8 + activated T cells in a cell-cell contact-dependent manner. Such a reduced proliferation in cell cocultures correlated with upregulation of programmed death ligand 1 on MSCs and cytotoxic T lymphocyte-associated Ag-4 (CTLA-4) on T cells, and increased production of interferon-g, interleukin-10, and prostaglandin E2. Importantly, and in contrast to PL-MSCs, both BM-MSCs and UCB-MSCs favored the generation of T-cell subsets displaying a regulatory phenotype CD4 + CD25 + CTLA-4 + . Our results indicate that, besides BM-MSCs, UCB-MSCs might be a potent and reliable candidate for future therapeutic applications.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Human Mesenchymal Stromal Cells from Adult and Neonatal Sources: A Comparative In Vitro Analysis of Their Immunosuppressive Properties Against T Cells

Castro-ManrrezaMarta

MayaniHéctor

García

et al. 2014

Stem Cells and Development

View full text Add to dashboard Cite

show abstract

“…Therefore, they can be used as a coadjuvant for the expansion of CD34 + cells [Zhang et al, 2004;Parolini et al, 2008] and have been tested for multiple applications, including neuroprotection in hypoxic-ischemic brain damage in a murine model [Ding et al, 2015], as a gene delivery vehicle [Chen et al, 2012] and for myocardial therapy [Makhoul et al, 2013]. Similar to bone marrow mesenchymal stem cells, placenta-derived stem cells inhibit Tcell proliferation and secretion of IFN-γ; the immunosuppressive activity of placenta-derived stem cells against T cells involves PD-L1 (programmed death-ligand 1, also known as CD274) [Luan et al, 2013;Tripathi and Guleria, 2015]. The placenta is also considered an important source of natural killer cells for potential applications in cellular immunotherapy [Kang et al, 2013].…”

Section: Placental Stem Cellsmentioning

confidence: 99%

The Placenta as an Organ and a Source of Stem Cells and Extracellular Matrix: A Review

Lobo¹,

Leonel²,

Miranda³

et al. 2016

Cells Tissues Organs

View full text Add to dashboard Cite

The placenta is a temporal, dynamic and diverse organ with important immunological features that facilitate embryonic and fetal development and survival, notwithstanding the fact that several aspects of its formation and function closely resemble tumor progression. Placentation in mammals is commonly used to characterize the evolution of species, including insights into human evolution. Although most placentas are discarded after birth, they are a high-yield source for the isolation of stem/progenitor cells and are rich in extracellular matrix (ECM), representing an important resource for regenerative medicine purposes. Interactions among cells, ECM and bioactive molecules regulate tissue and organ generation and comprise the foundation of tissue engineering. In the present article, differences among several mammalian species regarding the placental types and classifications, phenotypes and potency of placenta-derived stem/progenitor cells, placental ECM components and current placental ECM applications were reviewed to highlight their potential clinical and biomedical relevance.

show abstract

“…In the recent literature, PMSCs have been shown to have immunosuppressive properties by suppressing the activation and proliferation of T lymphocytes. 15,16 In addition, PMSCs show minimal to no immunogenicity. 17 …”

mentioning

confidence: 99%

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model

Zhao

Gillen

Harris

et al. 2014

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

Objective Bone marrow–derived mesenchymal stem cells (MSCs) have shown therapeutic potential in acute lung injury. Recently, placenta-derived human mesenchymal stem cells (PMSCs) have shown similarities with bone marrow–derived MSCs in terms of regenerative capabilities and immunogenicity. This study investigates the hypothesis that treatment with PMSCs reduces the development of bronchiolitis obliterans in a murine heterotopic tracheal transplant model. Methods A murine heterotopic tracheal transplant model was used to study the continuum from acute to chronic rejection. In the treatment groups, PMSCs or PMSC-conditioned medium (PMSCCM) were injected either locally or intratracheally into the allograft. Phosphate-buffered saline (PBS) or blank medium was injected in the control groups. Tracheal luminal obliteration was assessed on sections stained with hematoxylin and eosin. Infiltration of inflammatory and immune cells and epithelial progenitor cells was assessed using immunohistochemistry and densitometric analysis. Results Compared with injection of PBS, local injection of PMSCs significantly reduced luminal obliteration at 28 days after transplantation (P = .015). Intratracheal injection of PMSCs showed similar results to local injection of PMSCs compared with injection of PBS and blank medium (P = .022). Tracheas treated with PMSC/PMSCCM showed protection against the loss of epithelium on day 14, with an increase in P63+CK14+ epithelial progenitor cells and Foxp3+ regulatory T cells. In addition, injection of PMSCs and PMSCCM significantly reduced the number of neutrophils and CD3+ T cells on day 14. Conclusions This study demonstrates that treatment with PMSCs is protective against the development of bronchiolitis obliterans in an heterotopic tracheal transplant model. These results indicate that PMSCs could provide a novel therapeutic option to reduce chronic rejection after lung transplant.

show abstract

Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34+ cells: A comparison with human bone marrow-derived mesenchymal stem cells

Cited by 46 publications

References 21 publications

Human Mesenchymal Stromal Cells from Adult and Neonatal Sources: A Comparative In Vitro Analysis of Their Immunosuppressive Properties Against T Cells

Human Mesenchymal Stromal Cells from Adult and Neonatal Sources: A Comparative In Vitro Analysis of Their Immunosuppressive Properties Against T Cells

The Placenta as an Organ and a Source of Stem Cells and Extracellular Matrix: A Review

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model

Contact Info

Product

Resources

About